Another Phase 3 PAPILLON study recently found that Amivantamab treated with platinum-based chemotherapy demonstrated superior efficacy compared to chemotherapy alone in patients with EGFR-mutated NSCLC that has advanced following treatment with Osimertinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.